HOME >> BIOLOGY >> NEWS
St. Jude shows gene test not needed if cancer drug given in low doses

Investigators at St. Jude Children's Research Hospital have shown that when the cancer drug irinotecan is given in low doses for multiple days, it eliminates the need to delay treatment to perform costly genetic testing that determines if the patient is at risk for serious treatment side effects, such as neutropenia. Neutropenia is an abnormal reduction in the numbers of immune cells, called neutrophils; the disorder leaves individuals more vulnerable to infections.

The finding means that clinicians can begin treatment sooner and eliminate the cost of this specialized test, which determines if the child carries a variation in the gene UGT1A1 that is linked to this side effect of neutropenia. By giving the drug in small doses for two weeks instead of the standard single large dose once a month, children can begin treatment with irinotecan immediately. Irinotecan is used to treat childhood solid tumors such as neuroblastoma, sarcomas and kidney tumors.

A report on this study is in the June 20 issue of the Journal of Clinical Oncology.

UGT1A1 makes an enzyme that modifies the activated form of irinotecan, a molecule called SN-38, so the body can easily remove it. Variations of this enzyme, especially one called UGT1A1*28, do not work as well and allow SN-38 to remain in the body at high levels for an extended period of time, causing side effects.

Like many genes, UGT1A1 has a series of DNA building blocks called thymidine and adenine (TA) repeating several times just in front of the gene itself. This area, called the promoter region, acts as an on switch that triggers the reading of the gene. The normal UGT1A1 has six copies of TA in front of it, while UGT1A1*28 has seven.

Previous studies had shown that when adults who carry two copies of the UGT1A1*28 gene variation received a single high dose of irinotecan, they suffered severe diarrhea or neutropenia, said Clinton Stewart, Pharm.D., associate member of the St.
'"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-495-3061
St. Jude Children's Research Hospital
19-Jun-2007


Page: 1 2

Related biology news :

1. Clones on task serve greater good, evolutionary study shows
2. Research shows skeleton to be endocrine organ
3. An early ape shows its hand
4. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
5. Huntingtons disease study shows animal models on target
6. Research shows NPD1 protects a key component of vision
7. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
8. Chitin from lobster shell shows great healing and bio-stimulant properties
9. Study shows cane sugar, corn sweeteners have similar effects on appetite
10. New research shows vaginal bacteria vary among healthy women, need customized treatment
11. Global warming is evaporating Arctic ponds, new study shows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/25/2019)... ... September 25, 2019 , ... ... have placed over 20,000 dental implants for a variety of procedures, including single ... and pterygoid dental implants. Dental implants offer patients permanent tooth replacement ...
(Date:9/24/2019)... ... September 23, 2019 , ... Global molecular diagnostics company ... Holotype HLA and other Omixon products will be featured among 10 posters and ... Histocompatibility and Immunogenetics (ASHI) in Pittsburgh, PA. Omixon’s Lunch Symposium on Thursday ...
(Date:9/22/2019)... ... September 20, 2019 , ... A new ... client demands for precision medicine products. The report, Lab Instrumentation Markets for ... 2018, the pharma/bio sector is the largest source of demand for laboratory instrumentation. ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... , ... October 01, 2019 , ... Cheyenne is a ... Mimi, Cheyenne’s owner, owns and operates Rebel’s Run , which offers riding ... favorite amongst students and trail riding guests. Mimi describes her as her “go ...
(Date:10/3/2019)... BOSTON (PRWEB) , ... October 03, 2019 , ... Yesterday, ... 2-3, Asymmetrex founder and director, James L. Sherley, M.D., Ph.D., discussed important ... To an attendee audience including both developers and suppliers of clinical trials, in ...
(Date:9/24/2019)... (PRWEB) , ... September 24, 2019 , ... ... stem cell company, has completed training and site qualification for clinical trial sites ... of recruitment and screening of potential clinical trial participants. , Clinical trial sites ...
(Date:9/17/2019)... ... September 17, 2019 , ... Tucker, a Labrador retriever, was just a puppy ... was limping and lame on his right hip and elbow. At one year of ... “the worst case the vet had seen.” He was prescribed pain medications, both oral ...
Breaking Biology Technology:
Cached News: